Us Pharma

For Moneycontrol Pro Panorama June 11 edition: AI is reshaping India’s job market, wiping out white-collar roles while boosting efficienc

Moneycontrol Pro Panorama | Has Trump’s taking credit for the India-Pak ceasefire alienated India?

There are areas where India strictly doesn’t want foreigners—no matter how close they are—to interfere. It has been the country’s policy since independence

Moneycontrol Pro Panorama | Reforming US pharma will not be easy for Trump

For Moneycontrol Pro Panorama May 13 edition: China-US put a pause on trade war but rivalry is on, gold rally may be over, navigating market volatility, India’s weight loss drug market is shaping up well, and more

Chart of the Day: How Cipla built a billion-dollar US business in a decade

The company’s US revenues are projected to move closer to $900 million in FY24 and $1 billion in FY25, up from $148 million in FY15

Pain points ease for pharma companies, but no earnings upgrades yet

Raw material cost inflation eased and US revenues grew at most large drug firms in the December 2022 quarter

US price erosion triggers strategy rejig at Indian pharma

Drug suppliers rethink their investment strategy as continuous price erosion hurts profitability and returns from the US market

US pharma body disappointed over decision to support COVID-19 vaccine patent waiver

PhRMA which represents America's leading innovative biopharmaceutical research companies has said that the "decision will sow confusion between public and private partners, further weaken already strained supply chains and foster the proliferation of counterfeit vaccines.

COVID-19 vaccines are chance at salvation, financial and beyond, for drugmakers

For an industry demonised by consumers and politicians, the hunt for a vaccine “offers a path to redemption”

Expect drug pricing pressure to continue in next few years: GSK

The US market is seeing a shift in market dynamics and several factors lead to drug product pricing and there will be further pricing pressure over the next few years, said GSK Global Chief Executive Andrew Witty.